Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Shattuck Labs Q3 2026 Results: Net Loss of $25.2M, Loss Widens

Shattuck Labs reported a net loss of $55.1 million for the nine months ended September 30, 2026, compared to $36.2 million in the prior year period, driven primarily by a significant increase in research and development expenses. The company strengthened its balance sheet during the period, ending with $201.6 million in total current assets following common stock offerings and warrant exercises.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.01.0
Net income-25.2-10.1
EPS (diluted, $ a share)$-0.14$-0.14

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: STTK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Shattuck Labs, Inc.: key numbers

Share price
$4.66Close, Nov 16
Market cap
$475M
Shares outstanding
101.84MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Shattuck Labs, Inc.

All →
8:03 AM ET 8-K
Financial Results

Shattuck Labs Financial Results

Shattuck Labs reported financial results for the third quarter of 2026, highlighting the initiation of the RECEPTIVE-CD1 Phase 2b trial for SL-325 in Crohn’s disease. The company also announced plans to start a Phase 2 trial in hidradenitis suppurativa and reported a cash position of $115.3 million, providing a runway into 2028.

“We are very excited to begin Phase 2 clinical development with SL-325 in both Crohn’s disease and hidradenitis suppurativa. We believe these two studies will allow direct comparisons with the TL1A antibody class and evaluate the efficacy that may be left on the table due to the potential immunogenicity liabilities of TL1A antibodies.”

Taylor Schreiber, M.D., Ph.D., Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.